Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology
•
Internal Medicine
•
Hematology
•
Sickle Cell
•
Pediatric Hematology
•
Benign Hematology
When would you consider upfront eculizumab for sickle cell hyperhemolysis?
How long after eculizumab infusion would you wait before giving blood transfusions?
Related Questions
How would you approach secondary stroke prevention in an adult with Hemoglobin SC disease?
How do you counsel sickle cell patients on the use of G-CSF to treat neutropenia from other causes, like malignancy?
Is there any indication for hydroxyurea in patients with sickle cell trait?
What subset of sickle cell disease patients are you offering sickle cell disease gene therapy?
Is there any benefit to using desmopressin over vWF replacement therapy for vWD?
What is your strategy for optimizing hydroxyurea dosage in patients with symptomatic sickle cell disease, particularly for genotypes HbSS and HbS/Beta thal?
How do you approach the work-up for a patient with iron deficiency anemia who is not responding to oral iron therapy?
Would you consider continuing or re-trialing hydroxyurea for sickle cell patients after development of a leg ulcer?
How is your experience with point-of-care INR systems for home monitoring of vitamin K antagonists?
Can anti-cardiolipin or anti-beta-2 glycoprotein antibodies cause prolonged PTT in the absence of a lupus anticoagulant?